One-Year Outcomes of the Open-Label Extension of CHIASMA OPTIMAL, a Phase 3 Study of Oral Octreotide Capsules in Acromegaly

Background: Based on the CHIASMA OPTIMAL study, oral octreotide capsules (OOC) were recently approved in the US as a long-term maintenance therapy for patients with acromegaly previously responding to injectable octreotide or lanreotide, somatostatin receptor ligands (SRLs). Results on longer-term e...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Endocr Soc
Hauptverfasser: Samson, Susan Leanne, Nachtigall, Lisa B, Fleseriu, Maria, Molitch, Mark E, Giustina, Andrea, Ludlam, William Henry, Patou, Gary, Haviv, Asi, Biermasz, Nienke, Kennedy, Laurence, Sever, Mojca Jensterle, Manning, Patrick John, Elenkova, Atanaska, Melmed, Shlomo, Strasburger, Christian Joseph
Format: Artigo
Sprache:Inglês
Veröffentlicht: Oxford University Press 2021
Schlagworte:
Neuroendocrinology and Pituitary
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8090558/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvab048.1054
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge